Drug-radiation interactions in tumor blood vessels

D E Hallahan1, A Y Chen, M Teng

  • 1Department of Biomedical Engineering, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Insights

Tumor blood vessel destruction aids tumor regression. Combining antiangiogenic drugs with radiation therapy enhances this effect by targeting the tumor endothelium, potentially overcoming treatment resistance.

Area of Science:

  • Oncology
  • Vascular Biology
  • Radiation Oncology

Background:

  • Tumor vasculature obliteration is crucial for tumor regression.
  • Antiangiogenic agents are emerging in cancer clinical trials.
  • Ionizing radiation induces inflammation and a procoagulative state in tumor blood vessels.

Purpose of the Study:

  • To explore the interactions between antiangiogenic agents and ionizing radiation.
  • To investigate the role of the vascular endothelium in combined treatment efficacy.
  • To understand mechanisms that may prevent resistance to cancer therapies.

Main Methods:

  • Review of mechanisms of interaction between antiangiogenic agents and ionizing radiation.
  • Analysis of endothelial responses to radiation, including oxidative injury and inflammatory cascade.
  • Examination of how biological response modifiers affect irradiated tumor vasculature.

Main Results:

  • Radiation induces endothelial oxidative injury, promoting procoagulative and inflammatory responses.
  • Concurrent administration of proinflammatory and prothrombotic agents with radiation can cause vascular obliteration and tumor necrosis.
  • Interactions may occur at the vascular endothelium level, potentially mitigating resistance.

Conclusions:

  • The vascular endothelium is a key target for combined antiangiogenic and radiation therapies.
  • Targeting endothelial responses may offer a strategy to enhance tumor regression and overcome resistance.
  • Future clinical trial designs should incorporate the impact of radiation on the vascular endothelium.

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...